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Skeletal metastases are an incurable complication afflicting the majority of patients who die from advanced breast
cancer. They are most often osteolytic, characterized by net bone destruction and suppressed new bone formation.
Life expectancy from first diagnosis of breast cancer bone metastases is several years, during which time skeletal-
related events - including pain, fracture, hypercalcemia, and spinal cord compression - significantly degrade quality
of life. The bone marrow niche can also confer hormonal and chemo-resistance. Most treatments for skeletal
metastases target bone-destroying osteoclasts and are palliative. Recent results from the Breast cancer trials of Oral
Everolimus-2 trial suggest that agents such as the mammalian target of rapamycin inhibitor everolimus may have
efficacy against breast cancer bone metastases in part via stimulating osteoblasts as well as by inhibiting tumor
growth. Selective estrogen receptor modulators similarly inhibit growth of estrogen receptor-positive breast cancers
while having positive effects on the skeleton. This review discusses the future role of bone-anabolic agents for the
specific treatment of osteolytic breast cancer metastases. Agents with both anti-tumor and bone-anabolic actions
have been tested in the setting of multiple myeloma, a hematological malignancy that causes severe osteolytic
bone loss and suppression of osteoblastic new bone formation. Stimulation of osteoblast activity inhibits multiple
myeloma growth - a strategy that might decrease breast cancer burden in osteolytic bone metastases. Proteasome
inhibitors (bortezomib and carfilzomib) inhibit the growth of myeloma directly and are anabolic for bone. Drugs
with limited anti-tumor activity but which are anabolic for bone include intermittent parathyroid hormone and
antibodies that neutralize the WNT inhibitors DKK1 and sclerostin, as well as the activin A blocker sotatercept and
the osteoporosis drug strontium ranelate. Transforming growth factor-beta inhibitors have little tumor anti-
proliferative activity but block breast cancer production of osteolytic factors and are also anabolic for bone. Some
of these treatments are already in clinical trials. This review provides an overview of agents with bone-anabolic
properties, which may have utility in the treatment of breast cancer metastatic to the skeleton.Introduction
Almost 40,000 women die from advanced breast cancer
yearly in the US, the majority with bone metastases; 85%
of them will have bone-destructive (osteolytic) skeletal
lesions, which cause hypercalcemia, fracture, severe and
intractable bone pain, and nerve compression. Average
survival from time of diagnosis of bone metastasis is 2
to 3 years, and about 10% of women with breast cancer
already have metastases when first diagnosed [1]. Os-
teolytic metastases are characterized by not only bone
destruction but also the inhibition of normal formation
of new bone, worsening the skeletal insult caused by* Correspondence: jmchirgw@iu.edu
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reproduction in any medium, provided the ormetastatic tumor [2]. While breast cancer therapy focuses
largely on tumor cells, agents that target bone may not
only reduce skeletal-related events but also sensitize the
tumor to conventional therapies. The hematological ma-
lignancy, multiple myeloma (MM), though very diffe-
rent from breast cancer, also colonizes and attacks the
skeleton. Both tumor types, when lodged in the skeleton,
stimulate osteolytic bone destruction. Several classes of
agents against myeloma have actions on the osteoblast
lineage and might be useful against osteolytic metastases
in advanced breast cancer. Data are lacking that bone-
biosynthetic osteoblasts oppose breast cancer growth in
bone, but such a mechanism is documented in MM. The
potential application to breast cancer of agents with bone-
anabolic activity is the focus of this review.BioMed Central. The licensee has exclusive rights to distribute this article, in any
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Osteolytic bone metastases can be modeled as a vicious
cycle (Figure 1), in which tumor cells stimulate bone de-
struction via osteoclast activation, releasing active growth
factors from bone matrix, which in turn stimulate tumor
growth [2]. Bone is resorbed by rare cells of the hema-
topoietic lineage, multinucleated osteoclasts, whose for-
mation is controlled by the factor receptor activator of
nuclear factor kappa B ligand (RANKL), made by cells in
the osteoblastic lineage, including abundant osteocytes
embedded within mineralized bone matrix [3]. Tumor
cells stimulate bone production of RANKL, which can
be neutralized by osteoprotegerin (OPG) also made by
bone cells [4]. A pathologically increased RANKL/OPG
ratio results in net bone loss. Osteoclasts are the major
targets of current bone-specific palliative therapies for
skeletal metastases, including bisphosphonates and the
RANKL-neutralizing monoclonal antibody, denosumab
[5]. Osteoclast-targeted therapies are a mature frequently
reviewed field and not discussed here, since the available
agents are highly effective and unlikely to be further im-
proved. Targeting osteoclasts alone, though it blocks bone
destruction, is insufficient to restore skeletal integrity,osteolytic
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Hence, we focus on drugs (approved or in clinical devel-
opment) with stimulatory actions on cells of the osteoblast
lineage.
Roles of bone cells in normal bone remodeling
Bone is a dynamic tissue that is slowly remodeled by the
action of osteoclasts to remove packets of old bone, fol-
lowed by the synthesis of new bone by osteoblasts. The
osteoblast lineage is complex and incompletely under-
stood. Mesenchymal precursors differentiate into early,
proliferative osteoblasts, which mature into late biosyn-
thetic osteoblasts that lay down new bone. Some cells
of this lineage continue to differentiate into osteocytes:
these are long-lived cells embedded within bone matrix
and connected to one another and the bone surface via
intracanalicular processes. Osteocytes are the most
abundant bone cell type and as yet little studied in can-
cer/bone diseases. They are the major source of several
endocrine factors secreted by bone, including sclerostin
and fibroblast growth factor (FGF)23 [6]. In healthy indi-
viduals, bone formation and resorption are kept in long-Sost/DKK1
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Osteoporosis is the consequence of a modest net excess
of resorption over formation. Bone resorption is ele-
vated in all types of cancer/bone disease [7]. Osteolytic
lesions occur in 85% of breast cancer bone metastases
and in MM. Osteoblastic/osteosclerotic bone metasta-
ses occur in prostate cancer and in about 15% of breast
cancer patients with skeletal metastases [2]. Loss of the
balance between formation and resorption suggests that
coupling is disrupted by the presence of tumor through
unknown mechanisms. Complicating the issue is that
cells of the osteoblast lineage are the source of RANKL,
OPG, and the WNT inhibitor sclerostin. It is unlikely,
however, that biosynthetic late osteoblasts, which lay
down new bone, are the source of these factors.
Markers of bone resorption and formation
Biochemical markers of bone metabolism are either bone
cell-secreted products (such as alkaline phosphatase from
early osteoblasts and osteocalcin from late osteoblasts) or
metabolites of collagen formation and degradation. Both
resorption markers and alkaline phosphatase are increased
in most patients with cancer in response to treatments,
many of which cause drug-induced osteoporosis [7]. Thus,
bone markers do not provide information about changes
in osteoblast function in bone metastases, which are in-
ferred from laboratory experiments rather than clinical
data.
Evidence for suppression of osteoblasts by tumor cells
Osteoblasts are very difficult to identify histologically,
even when bone biopsies are available. Thus, the data
for osteoblast suppression, even in MM, are derived
mostly from observations in vitro rather than from the
clinic. Tumor suppression of osteoblasts is seen in vitro
and may be due to production by breast cancer cells of
IL-1 and IL-11, tumor necrosis factor-alpha, platelet-
derived growth factor, or Fas ligand or indirectly due to
osteoclastic activation of transforming growth factor-
beta (TGFβ) [8,9].
Restoration of lost bone is a major goal of osteoporosis
treatment
Restoration of lost bone is a major goal of osteoporosis
treatment, to which end a variety of bone-anabolic agents,
including once-a-day parathyroid hormone (PTH) and
strontium ranelate, have been developed. For the purposes
of this discussion, we define anabolic agents as those that
stimulate biosynthetic osteoblasts to synthesize new bone,
rather than drugs that stimulate all parts of the long and
complex osteoblast lineage. Several anti-tumor agents
have positive effects on bone health: proteasome inhibi-
tors (PIs) (bortezomib and carflizomib) are US Food and
Drug Administration (FDA)-approved for MM therapy[10]. Mammalian target of rapamycin (mTOR) inhibitors
have osteoblast-stimulatory as well as osteoclast- and
tumor-inhibitory actions [11]. Proof-of-principal for the
value of osteoblast stimulation in the treatment of osteo-
lytic breast cancer metastases was suggested by explo-
ratory studies of bone parameters (reviewed [11] in the
BOLERO-2 (Breast cancer trials of Oral Everolimus-2)
trial (exemestane + the mTOR inhibitor everolimus) [12].Selective estrogen receptor modulators
Selective estrogen receptor modulators (SERMs) (such as
tamoxifen and raloxifene) have anti-tumor activity against
estrogen receptor-positive (ER+) breast cancers while
also stimulating bone formation. Promising agents with
bone-anabolic actions that do not directly inhibit tumor
proliferation include TGFβ inhibitors and neutralizing
antibodies against the WNT inhibitors DKK1 and scler-
ostin (which are negative regulators of bone formation).
This review discusses the applicability of these agents
for breast cancer bone metastasis.Review
The role of anti-resorptive agents in the treatment of
bone metastases is well established. In addition to tumor-
induced osteolysis, conventional cancer treatments stimu-
late osteolysis, often by suppression of sex steroid activity
[13,14]. Some anti-cancer agents also have direct effects to
increase osteoclast activity, such as geldanamycin deriva-
tives, which make osteolytic metastases worse unless com-
bined with an anti-resorptive agent [15]. Bone marrow
provides a major tumor stem cell niche, which may be al-
tered in states of high bone turnover [16]. In a number of
animal models, experimental stimulation of bone turnover
increases skeletal metastases, suggesting that high bone
turnover is generally undesirable in cancer and should be
opposed with anti-resorptive drugs.
Inhibitors of osteoclastic bone resorption are the stand-
ard of care for all cancers growing in bone, whether the
overall bone response is osteolytic or osteoblastic [5].
Available agents fall into three classes: cathepsin K in-
hibitors, bisphosphonates, and RANKL-neutralizing anti-
body. Cathepsin K is a lysosomal enzyme with activity that
is essential during bone resorption by active osteoclasts
[17]. Bisphosphonates, such as zoledronic acid, are meta-
bolic poisons that bind avidly to mineral surfaces in bone,
whence they are ingested by active osteoclasts, which they
then kill. RANKL is expressed by cells in the osteoblast
lineage and controls the differentiation of osteoclasts from
hematopoietic precursors as well as their activity and sur-
vival [4]. Neutralization of RANKL with the monoclonal
antibody denosumab effectively blocks the formation of
osteoclasts. Denosumab appears to be the most effective
of the anti-resorptive agents. Some anti-cancer drugs can
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in patients already receiving potent anti-resorptive agents.
mTOR inhibitors and lessons from the BOLERO-2 trial
The phosphoinositide-3-kinase-Akt-mTOR pathway is a
key mediator of cellular proliferation, apoptosis, migra-
tion, and angiogenesis - all critical to tumor aggressiveness
[18]. It is commonly activated in breast cancer, conferring
resistance to hormonal therapy and trastuzumab. Block-
ade of the pathway at multiple levels overcomes resist-
ance, and inhibitors are in clinical development. The
mTOR inhibitors rapamycin, everolimus, and temsiroli-
mus are of particular interest for breast cancer bone me-
tastasis because they have positive actions on bone in
addition to sensitizing tumors to hormonal therapy and
trastuzumab. mTOR inhibition suppresses RANKL and
cathepsin K and increases OPG secretion by bone marrow
stromal cells [19]. Everolimus promotes osteoblast differ-
entiation and decreases bone loss associated with estrogen
deprivation in breast cancer models [20]. BOLERO-2 is a
phase III trial of everolimus plus the steroidal aromatase
inhibitor (AI) exemestane versus placebo plus exemestane
in women with metastatic ER+ breast cancer recurring or
progressing despite AI therapy [12]. The everolimus arm
showed a superior response rate (7% versus 0.4%) and
progression-free survival (10.6 versus 4.1 months), as well
as lowered bone resorption markers and decreased bone
progression across subgroups, regardless of bisphospho-
nate use and baseline bone metastases. Both everolimus-
mediated sensitization to exemestane and its bone effect
may contribute to the positive results of the combination.
The relative contribution of each mechanism cannot be
quantified in clinical studies, but an early reduction in
bone turnover markers prior to clinical response and the
reduced bone complications in the everolimus arm sup-
port bone targeting as a therapeutic strategy in breast can-
cer [11]. Whether everolimus-mediated bone benefit can
decrease future bone metastases will be answered by an
ongoing clinical trial exploring everolimus in an adjuvant
setting (ClinicalTrials.gov identifier: NCT01674140). The
benefits from everolimus point the way to new clinical tri-
als to test other novel agents with positive effects on bone,
including the src inhibitor desatinib, the c-met and vascu-
lar endothelial growth factor receptor (VEGFR)2 inhibitor
cabozantinib, and the phosphoinositide-3-kinase inhibitor
BKM120 in bone metastases due to breast, prostate, and
renal cancers.
Proteasome inhibitors
The proteasome degrades damaged, misfolded, and short-
lived proteins. Cancer cells are vulnerable to metabolic
stress caused by blockade of this pathway. Although high
proteasome activity is seen in many cancer types, PIs are
particularly cytotoxic to MM and mantle cell lymphoma.Two PIs, the first-in-class boronate peptide bortezomib
and the epoxyketone carfilzomib, are FDA approved for
myeloma treatment. Other anti-myeloma agents improve
bone health by killing MM cells, thereby reducing cancer-
induced osteoclastogenesis. PIs have additional, bone-
anabolic actions, suggesting their potential for use against
osteolytic solid tumor bone metastases. Bortezomib and
carfilzomib inhibit osteoclast formation and bone re-
sorption while enhancing osteoblastic differentiation and
mineralization in vitro [21,22]. Carfilzomib and its orally
active analog oprozomib increase trabecular bone volume
and decrease bone resorption in normal and MM-bearing
mice [23]. In patients with MM, bortezomib and carfilzo-
mib reduce markers of bone resorption but also increase
those of bone formation (alkaline phosphatase and osteo-
calcin) regardless of tumor response, suggesting direct
bone-anabolic effects [24,25].
The detailed mechanisms of the bone-anabolic actions
of PIs remain unclear but may result from enhanced
WNT/β-catenin signaling in osteoblasts due to decreased
DKK1 [26]. Bortezomib is cytotoxic for breast cancer cells
in vitro and suppresses tumor growth and osteolysis when
breast cancer cells are directly injected into the tibiae
of mice [27]. In clinical trials, bortezomib had marginal
single-agent efficacy against advanced disease, but bone
metastases were not analyzed in these studies [28]. Borte-
zomib has additive cytotoxicity when used in combination
with a broad array of current agents (such as doxorubicin
and paclitaxel) or those in development for breast cancer
(such as SAHA, Hsp90 inhibitors, and lapatinib). Com-
mon chemotherapeutics generally increase bone loss [7].
Incorporation of PI in a breast cancer treatment regimen
could enhance tumor killing, prevent further tumor
growth in bone, and improve bone health - an approach
worthy of clinical development.
Anti-tumor effects of osteoblasts
Data from patients with MM, experiments in animals,
and co-cultures of MM cells with bone cells all suggest
that osteoblasts and their products oppose growth of
MM cells in bone. This suggests a second vicious cycle
in cancer-bone interactions (Figure 1), in which MM and
other osteolytic cancers suppress osteoblasts to overcome
the growth-inhibitory effects of osteoblasts on tumor. The
marker of osteoblast activity, alkaline phosphatase, is sup-
pressed in MM, and co-culture with osteoblasts inhibits
MM cell growth, whereas their co-culture with osteoclasts
has the opposite effect [29]. The data suggest a model in
which osteoblast-secreted products, such as decorin, are
locally and specifically cytotoxic for MM cells. Similar
data exist in breast cancer. When breast cancer cells were
cultured on a bone substrate containing osteoclasts, the
introduction of osteoblasts decreased bone resorption
[30]. This effect is the opposite of what would be expected
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RANKL. Osteoclasts, on the other hand, catalyze the
release of a panoply of growth factors from their immo-
bilized storage site within bone matrix (Figure 1), which
stimulate breast cancer and MM growth, driving the
basic vicious cycle. Complicating the issue is the regulation
of osteoclast formation by RANKL, which is expressed by
subsets of cells in the multi-stage osteoblastic lineage.
Thus, a drug that stimulated RANKL+ cells in the osteo-
blast lineage could increase rather than decrease osteolysis
and tumor growth.
One bone-anabolic agent is currently widely used in the
treatment of osteoporosis: once-daily injection of PTH
1-34 (teriparatide). When given to experimental animals,
teriparatide increased new bone formation and resulted in
suppression of myeloma growth [31]. The authors pro-
posed that osteoblasts were stimulated to secrete anti-
myeloma factors. Identification of such factors would
facilitate development of more selective anti-myeloma
treatments that might also be effective against bone me-
tastases due to solid tumors, including breast cancer. The
authors isolated myelomatous bone from mice treated
with PTH or saline for 4 weeks and examined RNA for
changes in gene expression by array hybridization. PTH
increased many markers of osteoblast activity, such as
collagens and osteocalcin, but also altered members of
the WNT signaling pathway, including reducing DKK1
mRNA, but not sclerostin. Teriparatide carries a black
box warning against its use in patients with cancer, due
to an increase in osteosarcomas in rats treated with
high doses of PTH, and is unlikely to be approved for
use in oncology. Nonetheless, the anti-tumor effects of
PTH provide proof-of-principal for the use of bone-
anabolic agents against myeloma bone disease and osteo-
lytic breast metastases. The anabolic actions of drugs can
be tested on bone separately from their effects on tumor
growth, as has been done for proteasome inhibitors and
MM. However, it is very difficult to evaluate the relative
contributions to anti-tumor efficacy of a multi-tasking
agent with both direct, anti-tumor and indirect, bone-
anabolic actions. A potent bone-anabolic agent without
direct actions on breast cancer growth might be useful
against bone metastases in the clinic.Roles of osteocytes
The osteoblastic lineage is complex, spanning many weeks
and phenotypes. Cells in the lineage not only lay down
new bone, they regulate osteoclasts via RANKL/OPG,
while late osteoblasts can become osteocytes, the cells im-
mured in mineralized matrix and interconnected by den-
dritic processes running in a canalicular network within
bone. Osteocytes are very long-lived and the most abun-
dant cell type in bone, compared with osteoblasts and rareosteoclasts. Because of their entrapment in bone matrix,
they are difficult to study in conventional tissue culture;
however, they are now known to make RANKL and to be
the major site of sclerostin production. Osteocytes are re-
sistant to apoptosis, but their numbers are decreased in
bone chronically exposed to myeloma cells. Maturation of
late osteoblasts into osteocytes may be blocked by factors
made by MM or breast cancer, or osteocytes may be re-
programmed by the local presence of tumor cells. MM
cells can cause osteocyte apoptosis and also contribute to
increased osteolysis by stimulating osteocyte production
of IL-11 [32].Selective estrogen receptor modulators and negative
effects on bone of aromatase inhibitors
SERMs interact with ERs in target organs as either ligand
agonists or antagonists. The main anti-estrogen treatments
are SERMs, such as tamoxifen, and third-generation AIs,
such as exemestane, letrozole, and anastrozole. AIs have
replaced tamoxifen in the past decade in the adjuvant
setting because of the lack of thromboembolic and uterine
cancer side effects and improved disease-free survival.
Over 80% of breast cancers are ER+. Therefore, these
agents have been extensively used at various stages of
breast cancer from prevention in high-risk populations
to neoadjuvant therapy in advanced-stage disease, both
alone and in combination with chemotherapy. However,
AIs reduce bone mineral density (BMD) and increase
fractures, whereas tamoxifen preserves BMD in post-
menopausal women [33]. The effect of AIs is only partly
attenuated by bisphosphonates. Mortality rate at 3 months
after hip fracture is higher with age [34], suggesting that
some patients treated with AIs will die from complications
of therapy and not from cancer. The data highlight the
possible long-term harm of cancer therapy and the need
to identify patients at highest risk for bone complications
as well as to develop strategies to overcome excessive
bone loss associated with AIs.Other agents with possible anabolic actions
Strontium ranelate effectively reduced osteoporotic verte-
bral fractures in clinical trials, whereas in vitro it can in-
hibit bone resorption and stimulate bone formation. The
clinical data are contradictory and the cellular mecha-
nisms unclear [35]; the agent was recently found to in-
crease the relative risk of myocardial infarction and is
unlikely to be approved for clinical use in the US. Substi-
tution of Sr for Ca in bone mineral is the basis for using
the beta emitter 89Sr for the palliation of metastatic bone
pain - an application different than that of the non-
radioactive element. Sr may be an anti-fracture agent
and not a bone-anabolic agent but might still be effec-
tive against bone metastases [36].
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Cabozantinib inhibits multiple receptor tyrosine kinases,
including MET and VEGFR2; it has direct anti-tumor ac-
tivity and may also stimulate normal bone formation in
patients with advanced prostate cancer [37]. A number of
pan-fibroblast growth factor receptor (FGFR) kinase in-
hibitors are in clinical trials [38], and one, NVP-BGJ398,
enhanced bone growth and mineralization in a mouse
model [39]. Pan-FGFR inhibitors were originally expected
to be effective against tumors with specific FGFR overex-
pression (and hence addicted to FGFR signaling). More
recently, pan-FGFR inhibitors have been brought into
clinical trials for tumors without FGF-signaling addiction.
Such inhibitors - and multi-kinase inhibitors that share
anti-pan-FGFR activity, such as dovitinib, nintedanib, and
ponatinib - may also have value for the specific treatment
of breast cancer bone metastases by adding bone-anabolic
actions to direct tumor inhibition.
Inhibitors of transforming growth factor beta superfamily
members
The TGFβ superfamily of over 30 ligands includes TGFβs,
activins, and bone morphogenetic proteins (BMPs). The
ligands signal through a complex array of heterodimeric
serine/threonine kinase receptors that activate intracellu-
lar Smad signaling pathways [40]. Members of each family
within the superfamily are active in cancer and bone, and
several have well-characterized effects on bone anabolism.
Activin A
Activin A is a multifunctional cytokine of the TGFβ
superfamily. It contributes to a broad range of cellular
pathways, including bone homeostasis, bone marrow
erythropoiesis, and skeletal muscle mass. It is abnor-
mally regulated in cancers, including breast, prostate,
ovarian, and hepatocellular carcinoma, and has been as-
sociated with tumor aggressiveness [41]. Activin A sig-
nals through the type 2A receptors on bone cells (both
osteoblasts and osteoclasts) and stromal cells. Its role in
both bone resorption and bone formation suggests that
inhibitors would be bone-anabolic agents. Vallet and
colleagues [42] found that activin A was elevated in
both the bone marrow and peripheral blood of patients
with MM. Co-culture with MM cells increases activin A
in bone marrow stromal cells and osteoclasts. Terpos
and colleagues [43] correlated activin A to extent of
bone involvement and poor survival in patients with
MM. Activin A receptor antagonists increase bone for-
mation in monkeys and in postmenopausal women as
well as prevent development of MM bone lesions and
decrease tumor burden in a murine model of MM, sug-
gesting that they enhance bone formation in vivo [42,44].
A recently completed phase II randomized trial of sotater-
cept (ACE-011), a soluble activin receptor type 2A IgG-Fcfusion protein, in MM patients with osteolytic lesions
(ClinicalTrials.gov identifier NCT00747123) showed in-
creased bone-specific alkaline phosphatase and decreased
bone resorption marker C-terminal telopeptide (CTX),
when used with melphalan and prednisone, compared
with melphalan + prednisone controls, in bisphosphonate-
na?ve patients. Sotatercept also promotes red blood cell
production and therefore was evaluated in a phase II
trial of patients with chemotherapy-induced anemia
and metastatic breast cancer [45]. Although improvement
of hemoglobin and a favorable toxicity profile were ob-
served, bone was not included as an endpoint in the study.
A similar fusion protein increased bone formation and
inhibited growth of breast cancer and MM in bone in pre-
clinical models [46]. The benefit of activin A antagonists
against solid tumor bone metastases certainly warrants
further evaluation.
Transforming growth factor beta inhibitors
TGFβ is a two-edged sword in cancer. It is a tumor sup-
pressor early in tumorigenesis, but breast cancers pro-
gress to escape its growth inhibitory effects and respond
to TGFβ by increasing expression of prometastatic genes
[47]. Mineralized bone matrix is the major store of im-
mobilized TGFβ in the body, whence it is released and
activated by osteoclastic bone resorption; TGFβ thus plays
a specific and important role in bone metastases as well as
in normal bone metabolism. Inhibition of TGFβ with
neutralizing antibodies or receptor kinase inhibitors is
effective against animal models of breast cancer bone
metastases and may reach the clinic [47]. Selective small-
molecule inhibition of the TGFβ type I receptor kinase is
anabolic for bone while suppressing osteoclasts [48], sug-
gesting that such inhibitors may have triple actions to in-
hibit tumor and osteoclasts while stimulating osteoblasts.
A downstream mediator of the effects of TGFβ is
tumor-secreted Jagged1, which activates Notch signaling
on bone stromal cells to increase pro-osteolytic IL-6 - a
process that can be blocked with a γ-secretase inhibitor
[49], but it is not known whether γ-secretase inhibitors
have bone-anabolic activity.
WNT inhibitor blockers
BMP and WNT pathways are major regulators of nor-
mal osteogenesis. WNT signaling is inhibited by specific
antagonists - sclerostin, DKK1, and secreted frizzled-
related proteins [50] - resulting in reduction of new bone
formation to basal levels. All three inhibitory proteins
can be made by tumors and bone and may contribute
to osteoblast suppression [51]. Breast cancer cells make
sclerostin and DKK1, whereas serum DKK1 is increased
in patients and contributes to osteolytic bone destruction
in breast cancer bone metastases [52]. Production of scler-
ostin by breast cancer cells blocks osteoblast differentiation
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cells, the WNT antagonists show specific effects on bone,
where they depress bone formation to a basal level rather
than blocking it entirely. DKK1 is made by MM cells and
increased in patient sera. A Dkk1-neutralizing antibody is
in clinical trials for MM [54], and sclerostin-neutralizing
antibodies have been developed for osteoporosis [55].
Neutralization of WNT inhibitors might be effective
against breast cancer bone metastases.
Summary of potential agents for bone metastases with
bone-anabolic activity
US Food and Drug Administration approved agents
The mTOR inhibitor everolimus is in use in the US for
metastatic breast cancer, following the BOLERO-2 trial.
Other mTOR inhibitors are FDA approved for other in-
dications and may have similar effects. SERMs such as
tamoxifen and raloxifene are approved but have been
largely superseded by AIs with their superior effects on
overall survival. PIs are approved in myeloma and have
been in clinical trials in breast cancer, although bone
metastases were not included [28]. On the basis of the
strong preclinical results from the Lian laboratory [27],
bortezomib merits further clinical trials in breast cancer
with inclusion of bone metastases.
Agents in clinical trials
Agents in clinical trials include drugs that neutralize
activin A or TGFβ or block their receptors. Many tyro-
sine kinase inhibitors may have bone-anabolic activities.
We will know whether these agents are useful against
bone metastases only if breast cancer trials enroll pa-
tients with confirmed bone metastases. Where such data
are lacking, candidate agents need to be tested in pre-
clinical models of breast cancer bone metastases to in-
form the design of clinical trials to include endpoints for
bone morbidity and tumor growth in bone. Antibodies
that neutralize DKK1 or sclerostin are in trials [54,55]
and may have beneficial effects to relieve the suppres-
sion of bone formation caused by these WNT inhibitors,
which can be made by breast cancer cells and myeloma
as well as by bone (osteocytes in the case of sclerostin).
Future targets
Future targets are the BMP pathway in bone and
osteoclast-osteoblast coupling factors (ephrins and sema-
phorins). The BMPs form another branch of the TGFβ
superfamily. BMP2 and BMP4 are made by osteoblasts
and stimulate osteogenesis. Although BMP2 can be made
by breast cancer cells, BMP2 and BMP7 are growth-
inhibitory for tumor cells and their bone metastases
[47], suggesting that anabolic effects on bone may not
be paramount in this context. There are 14 BMP ligands
and many secreted BMP antagonists and binding proteins,such as noggin, which enhances breast cancer bone me-
tastases [56]. Contrary effects of individual BMPs and an-
tagonists on tumor versus bone make this a complex and
unpredictable area of metastasis study, despite the ana-
bolic actions of BMPs on bone.
During normal bone homeostasis, mineral removal (by
osteoclasts) and formation (by osteoblasts) are kept in
balance by incompletely understood coupling mecha-
nisms involving local signaling between the two bone
cell types. Two candidate pathways involve ephrins and
semaphorins. For example, osteoclasts express ephrin B2,
which stimulates osteoblasts via binding to the EphB4
receptor to stimulate new bone formation [57]. The
pathway is dysregulated in the bone of patients with
MM [58]. Osteoclasts may also express semaphorin 4D,
which suppresses bone formation via receptors on nearby
osteoblasts to oppose new bone while resorption is on-
going [59]. Osteocytes may also regulate coupling in bone
[6], but it is unknown whether these cells are responsive
to bone-anabolic agents. The positive and negative coup-
ling pathways offer targets for novel drugs to stimulate
bone formation in osteoporotic patients. Such drugs have
obvious potential in the treatment of breast cancer bone
metastases. Coupling factors represent a young area of re-
search in bone, where additional pathways may be found
that provide targets for the future treatment of osteolytic
bone metastases in patients with advanced breast cancer.
Conclusions
Breast cancer bone metastasis and MM are very different
tumor types but share an affinity for advanced disease to
grow in bone. MM growth is accompanied by suppression
of osteoblastic new formation and increased osteolytic
bone destruction. In myeloma, several agents with bone-
anabolic activities successfully inhibit tumor growth. Fac-
tors secreted from mature, bone-synthesizing osteoblasts
may also have anti-tumor activity against metastatic can-
cer. Agents already in use against MM (such as bortezomib
and other PIs) or for osteoporosis (strontium ranelate) may
be effective, low-toxicity treatments for breast cancer bone
metastases. Other agents in clinical trials - in particular,
neutralizing antibodies against sclerostin and DKK1 and
activin A-blocking reagents - could show similar efficacy in
bone metastasis-specific clinical settings.
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